Dake Benjamin T. - 08 Aug 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Officer Title: President, Chief Operating Officer and Secretary
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
08 Aug 2022
Net transactions value
-$353,068
Form type
4
Filing time
10 Aug 2022, 17:15:22 UTC
Previous filing
16 Dec 2021
Next filing
12 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $12,081 +6,943 $1.74* 6,943 08 Aug 2022 Direct F1
transaction AVTE Common Stock Sale $97,283 -3,989 -57% $24.39 2,954 08 Aug 2022 Direct F1, F2
transaction AVTE Common Stock Sale $73,678 -2,954 -100% $24.94 0 08 Aug 2022 Direct F1, F3
transaction AVTE Common Stock Options Exercise $15,138 +8,700 $1.74* 8,700 09 Aug 2022 Direct F1
transaction AVTE Common Stock Sale $140,889 -5,909 -68% $23.84 2,791 09 Aug 2022 Direct F1, F4
transaction AVTE Common Stock Sale $68,436 -2,791 -100% $24.52 0 09 Aug 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -6,943 -14% $0.000000 41,350 08 Aug 2022 Common Stock 6,943 $1.74 Direct F1, F6
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -8,700 -21% $0.000000 32,650 09 Aug 2022 Common Stock 8,700 $1.74 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.80 to $24.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.81 to $25.43, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.34 to $24.34, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.345 to $24.70, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: President, Chief Operating Officer and Secretary